JP2013512694A - 養子細胞療法のための細胞を培養する方法 - Google Patents

養子細胞療法のための細胞を培養する方法 Download PDF

Info

Publication number
JP2013512694A
JP2013512694A JP2012543271A JP2012543271A JP2013512694A JP 2013512694 A JP2013512694 A JP 2013512694A JP 2012543271 A JP2012543271 A JP 2012543271A JP 2012543271 A JP2012543271 A JP 2012543271A JP 2013512694 A JP2013512694 A JP 2013512694A
Authority
JP
Japan
Prior art keywords
cells
cell
growth
surface density
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012543271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512694A5 (https=
Inventor
エフ． ベラ、フアン
エム． ルーニー、クリオ
エム． リーン、アン
アール． ウィルソン、ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wilson Wolf Manufacturing LLC
Original Assignee
Wilson Wolf Manufacturing LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilson Wolf Manufacturing LLC filed Critical Wilson Wolf Manufacturing LLC
Publication of JP2013512694A publication Critical patent/JP2013512694A/ja
Publication of JP2013512694A5 publication Critical patent/JP2013512694A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2012543271A 2009-12-08 2010-12-08 養子細胞療法のための細胞を培養する方法 Pending JP2013512694A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26776109P 2009-12-08 2009-12-08
US61/267,761 2009-12-08
PCT/US2010/059591 WO2011072088A2 (en) 2009-12-08 2010-12-08 Improved methods of cell culture for adoptive cell therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015095864A Division JP2015133997A (ja) 2009-12-08 2015-05-08 養子細胞療法のための細胞を培養する方法

Publications (2)

Publication Number Publication Date
JP2013512694A true JP2013512694A (ja) 2013-04-18
JP2013512694A5 JP2013512694A5 (https=) 2014-01-30

Family

ID=44082417

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012543271A Pending JP2013512694A (ja) 2009-12-08 2010-12-08 養子細胞療法のための細胞を培養する方法
JP2015095864A Pending JP2015133997A (ja) 2009-12-08 2015-05-08 養子細胞療法のための細胞を培養する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015095864A Pending JP2015133997A (ja) 2009-12-08 2015-05-08 養子細胞療法のための細胞を培養する方法

Country Status (8)

Country Link
US (1) US8809050B2 (https=)
EP (2) EP2510086A4 (https=)
JP (2) JP2013512694A (https=)
CN (1) CN102762719A (https=)
CA (1) CA2783550A1 (https=)
IL (1) IL220232A0 (https=)
SG (1) SG181559A1 (https=)
WO (1) WO2011072088A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015133997A (ja) * 2009-12-08 2015-07-27 ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 養子細胞療法のための細胞を培養する方法
JP2016530895A (ja) * 2013-09-23 2016-10-06 ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 動物細胞を遺伝子改変する改良された方法
US9567565B2 (en) 2009-12-08 2017-02-14 Juan F. Vera Methods of cell culture for adoptive cell therapy
CN110199016A (zh) * 2016-11-17 2019-09-03 艾欧凡斯生物治疗公司 残余肿瘤浸润淋巴细胞及其制备和使用方法

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
WO2012129201A1 (en) * 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN104769104A (zh) 2011-12-12 2015-07-08 细胞药物有限公司 扩大t细胞的方法
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
SG11201407226WA (en) * 2012-05-18 2014-12-30 Wolf Wilson Mfg Corp Improved methods of cell culture for adoptive cell therapy
CN104411819B (zh) * 2012-06-11 2019-05-10 威尔逊沃夫制造公司 用于过继细胞疗法的改进的细胞培养方法
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CN118562610A (zh) * 2013-06-24 2024-08-30 威尔逊沃夫制造公司 用于透气性细胞培养过程的封闭系统装置和方法
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
CN105418766A (zh) * 2015-12-22 2016-03-23 深圳市北科生物科技有限公司 一种用于免疫治疗的eb病毒lmp2a串联表位肽及其应用
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
CN109843921B (zh) 2016-07-07 2023-05-26 艾欧凡斯生物治疗公司 程序性死亡1配体1(pd-l1)结合蛋白及其应用方法
MX2019004707A (es) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
BR112019013940A2 (pt) 2017-01-06 2020-02-11 Iovance Biotherapeutics, Inc. Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
WO2018195014A1 (en) 2017-04-19 2018-10-25 Neubiser Richard Bioreactor for biological material
US20200224161A1 (en) 2017-05-10 2020-07-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
EP3635097A1 (en) 2017-06-05 2020-04-15 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
EP4501408A3 (en) 2017-11-17 2025-04-09 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
EP3724885A2 (en) 2017-12-15 2020-10-21 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
MA52667B1 (fr) 2018-03-29 2024-07-31 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
US20210130779A1 (en) 2018-04-27 2021-05-06 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
CA3112599A1 (en) 2018-09-20 2020-03-26 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
US20230039976A1 (en) 2018-11-05 2023-02-09 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
TW202039830A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
TW202039831A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療
JP7710372B2 (ja) 2018-12-19 2025-07-18 アイオバンス バイオセラピューティクス，インコーポレイテッド 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
JP2022553389A (ja) 2019-10-25 2022-12-22 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
WO2021123832A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
AU2021217003A1 (en) 2020-02-04 2022-09-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Anti-dinitrophenol chimeric antigen receptors
US12159700B2 (en) 2020-04-22 2024-12-03 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
TW202208616A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 改良之腫瘤反應性ｔ細胞的選擇
EP4146794A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
TW202241468A (zh) 2020-12-11 2022-11-01 美商艾歐凡斯生物治療公司 用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
CA3202483A1 (en) 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
AU2022246174A1 (en) 2021-03-25 2023-09-14 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
EP4326287A2 (en) 2021-04-19 2024-02-28 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
US20240342285A1 (en) 2021-07-28 2024-10-17 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4430167A1 (en) 2021-11-10 2024-09-18 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
US20250101380A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10290689A (ja) * 1997-04-18 1998-11-04 Hitachi Chem Co Ltd リンパ球細胞の製造法及び免疫治療剤
JPH11187868A (ja) * 1997-12-26 1999-07-13 Teijin Ltd ウィルスまたは細胞の培養法
WO2005051927A1 (ja) * 2003-11-26 2005-06-09 Kureha Corporation Hiv-1感染末梢血単核球の刺激培養によるcd4陽性ｔ細胞の培養方法、及びhiv-1の増殖阻害剤
JP2007061020A (ja) * 2005-08-31 2007-03-15 Takara Bio Inc リンパ球の製造方法
WO2008023786A1 (en) * 2006-08-25 2008-02-28 Medical & Biological Laboratories Co., Ltd. Method for producing virus-specific ctl

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649118A (en) * 1984-04-05 1987-03-10 The Virtis Company, Inc. Cell culturing apparatus with improved stirring and filter means
US5248769A (en) * 1985-06-26 1993-09-28 Cetus Oncology Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US5731160A (en) * 1992-05-26 1998-03-24 Rijksuniversiteit Leiden Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
US5707869A (en) * 1994-06-28 1998-01-13 Wolf; Martin L. Compartmentalized multiple well tissue culture plate
US5585266A (en) * 1995-10-05 1996-12-17 Plitt; Cheryl A. Immobilized cell bioreactor
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
JPH10174581A (ja) 1996-12-16 1998-06-30 Kikkoman Corp 培養容器
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
KR100895231B1 (ko) * 2002-03-25 2009-05-04 다카라 바이오 가부시키가이샤 세포상해성 림프구의 제조방법
US20070020752A1 (en) 2003-05-22 2007-01-25 Pall Corporation Cell culturing device and system
CN101120083B (zh) * 2003-10-08 2013-03-27 威尔森沃尔夫制造公司 利用透气性材料进行细胞培养的方法及装置
WO2005047466A2 (en) 2003-11-04 2005-05-26 Case Western Reserve University Apparatus and method for tissue engineering
WO2006026746A2 (en) 2004-08-31 2006-03-09 The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to separate and expand antigen-specific t cells
MX2009009168A (es) * 2007-02-27 2009-09-07 Int Inst Cancer Immunology Inc Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
US9410113B2 (en) * 2007-10-26 2016-08-09 St3 Development Corporation Bioreactor system for three-dimensional tissue stimulator
US8809050B2 (en) 2009-12-08 2014-08-19 Wilson Wolf Manufacturing Methods of cell culture for adoptive cell therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10290689A (ja) * 1997-04-18 1998-11-04 Hitachi Chem Co Ltd リンパ球細胞の製造法及び免疫治療剤
JPH11187868A (ja) * 1997-12-26 1999-07-13 Teijin Ltd ウィルスまたは細胞の培養法
WO2005051927A1 (ja) * 2003-11-26 2005-06-09 Kureha Corporation Hiv-1感染末梢血単核球の刺激培養によるcd4陽性ｔ細胞の培養方法、及びhiv-1の増殖阻害剤
JP2007061020A (ja) * 2005-08-31 2007-03-15 Takara Bio Inc リンパ球の製造方法
WO2008023786A1 (en) * 2006-08-25 2008-02-28 Medical & Biological Laboratories Co., Ltd. Method for producing virus-specific ctl

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11268066B2 (en) 2009-12-08 2022-03-08 Wilson Wolf Manufacturing Methods of cell culture for adoptive cell therapy
US9567565B2 (en) 2009-12-08 2017-02-14 Juan F. Vera Methods of cell culture for adoptive cell therapy
US12454667B2 (en) 2009-12-08 2025-10-28 Wilson Wolf Manufacturing, LLC Methods of cell culture for adoptive cell therapy
JP2015133997A (ja) * 2009-12-08 2015-07-27 ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 養子細胞療法のための細胞を培養する方法
US10533156B2 (en) 2009-12-08 2020-01-14 Baylor College Of Medicine Methods of cell culture for adoptive cell therapy
US11999969B2 (en) 2009-12-08 2024-06-04 Wilson Wolf Manufacturing Methods of cell culture for adoptive cell therapy
JP2016530895A (ja) * 2013-09-23 2016-10-06 ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 動物細胞を遺伝子改変する改良された方法
JP2019534030A (ja) * 2016-11-17 2019-11-28 アイオバンス バイオセラピューティクス，インコーポレイテッド レムナント腫瘍浸潤リンパ球並びにそれを調製及び使用する方法
US11293009B2 (en) 2016-11-17 2022-04-05 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
US11401507B2 (en) 2016-11-17 2022-08-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
JP7125392B2 (ja) 2016-11-17 2022-08-24 アイオバンス バイオセラピューティクス，インコーポレイテッド レムナント腫瘍浸潤リンパ球並びにそれを調製及び使用する方法
JP2022167931A (ja) * 2016-11-17 2022-11-04 アイオバンス バイオセラピューティクス，インコーポレイテッド レムナント腫瘍浸潤リンパ球並びにそれを調製及び使用する方法
US11220670B2 (en) 2016-11-17 2022-01-11 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
US12233075B2 (en) 2016-11-17 2025-02-25 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
JP7675688B2 (ja) 2016-11-17 2025-05-13 アイオバンス バイオセラピューティクス，インコーポレイテッド レムナント腫瘍浸潤リンパ球並びにそれを調製及び使用する方法
CN110199016A (zh) * 2016-11-17 2019-09-03 艾欧凡斯生物治疗公司 残余肿瘤浸润淋巴细胞及其制备和使用方法

Also Published As

Publication number Publication date
SG181559A1 (en) 2012-07-30
EP2698430A3 (en) 2014-03-05
JP2015133997A (ja) 2015-07-27
EP2698430A2 (en) 2014-02-19
CA2783550A1 (en) 2011-06-16
US8809050B2 (en) 2014-08-19
WO2011072088A2 (en) 2011-06-16
IL220232A0 (en) 2012-07-31
WO2011072088A3 (en) 2011-10-13
EP2510086A2 (en) 2012-10-17
US20110136228A1 (en) 2011-06-09
CN102762719A (zh) 2012-10-31
EP2510086A4 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
JP2015133997A (ja) 養子細胞療法のための細胞を培養する方法
JP7346526B2 (ja) 養子細胞療法のための改良された細胞培養法
US11999969B2 (en) Methods of cell culture for adoptive cell therapy
JP4185366B2 (ja) 抗原−特異的Ｔｒ１リンパ球を得る方法
JP2004527263A (ja) 免疫抑制活性を有するエクスビボ単離ｃｄ２５＋ｃｄ４＋ｔ細胞とその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150721